sub:assertion {
  d:DB00215 dv:ddi-interactor-in dr:DB00215_DB06414 .
  d:DB06414 dv:ddi-interactor-in dr:DB00215_DB06414 .
  dr:DB00215_DB06414 dct:identifier "drugbank_resource:DB00215_DB06414" ;
    dct:title """DDI between Citalopram and Etravirine - Citalopram, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience an increase in serum concentration.

It is recommended to maintain the dose of citalopram below 20mg/day, and to monitor for toxicity. The symptoms which often accompany citalopram overdose are dizziness, sweating, nausea, vomiting, tremor, somnolence,sinus tachycardia,amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, acute renal failure, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and torsade de pointes)."""@en ;
    a dv:Drug-Drug-Interaction ;
    rdfs:label """DDI between Citalopram and Etravirine - Citalopram, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience an increase in serum concentration.

It is recommended to maintain the dose of citalopram below 20mg/day, and to monitor for toxicity. The symptoms which often accompany citalopram overdose are dizziness, sweating, nausea, vomiting, tremor, somnolence,sinus tachycardia,amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, acute renal failure, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and torsade de pointes).  [drugbank_resource:DB00215_DB06414]"""@en .
}